nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00001465,Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM),,Recruiting,Observational,Lung Disease; Pneumothorax; Tuberous Sclerosis; Lymphangioleiomyomatosis,Toshibia Aquilion One CT,,"National Heart, Lung, and Blood Institute (NHLBI)",,2000,1995-12-18,,United States,No,https://clinicaltrials.gov/study/NCT00001465
NCT00033137,"Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts",,Recruiting,Observational,"Kidney Neoplasms; Kidney Cancer; Pneumothorax; FLCN Protein, Human",,,National Cancer Institute (NCI),,950,2002-05-13,,United States,No,https://clinicaltrials.gov/study/NCT00033137
NCT00068003,Cell Harvest and Preparation for Surgery Branch Treatment Protocols,,Enrolling by invitation,Observational,Melanoma; Gastrointestinal Cancer; Metastatic Cancer; Breast Cancer; Non-Small Cell Lung Cancer,Anti-CD19 CAR PBL,,National Cancer Institute (NCI),,7000,2003-09-08,,United States,No,https://clinicaltrials.gov/study/NCT00068003
NCT01970696,International Ovarian & Testicular Stromal Tumor Registry,,Recruiting,Observational,Ovarian Sex-cord Stromal Tumor; Testicular Stromal Tumors; Ovarian Small Cell Carcinoma,,,Children's Hospitals and Clinics of Minnesota,"Children's National Research Institute; Dana-Farber Cancer Institute; Washington University School of Medicine; University of Texas Southwestern Medical Center; M.D. Anderson Cancer Center; Children's Hospital Colorado; Rutgers University; Massachusetts General Hospital; Klinikum Dortmund Wirbelsäulenchirurgie; ResourcePath, LLC; Allina Health System; Phoenix Children's Hospital; University of Cambridge",300,2011-12-08,2030-12-05,United States,No,https://clinicaltrials.gov/study/NCT01970696
NCT02178163,A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.,Not Applicable,Recruiting,Interventional,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,cytology specimen collection procedure; laboratory biomarker analysis,,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),1020,2014-08-01,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT02178163
NCT02596490,Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners,Not Applicable,Recruiting,Interventional,Lung Cancer,Questionnaires; Meditation and Discussion Sessions; Cancer-Related Discussion Program,,M.D. Anderson Cancer Center,"National Cancer Institute (NCI); American Cancer Society, Inc.",300,2016-04-06,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT02596490
NCT03465774,A Prospective Observational Cohort Study of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions,,Recruiting,Observational,Pleural Neoplasm,Doxycycline; Indwelling Catheter; Quality-of-Life Assessment; Questionnaire Administration; Survey Administration,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),208,2018-03-08,2028-12-01,United States,No,https://clinicaltrials.gov/study/NCT03465774
NCT03586453,A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Osimertinib,,Dana-Farber Cancer Institute,AstraZeneca,30,2018-08-13,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT03586453
NCT03774758,Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening,,Recruiting,Observational,Nodule Solitary Pulmonary; Non-small Cell Lung Cancer,Guardant Health ct-DNA LUNAR assay,,"University of California, San Francisco","Northern California Institute of Research and Education; Guardant Health, Inc.",590,2017-12-17,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT03774758
NCT03948100,"Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers",Not Applicable,Recruiting,Interventional,Esophageal Carcinoma; Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Educational Intervention; Quality-of-Life Assessment; Questionnaire Administration; Yoga,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),400,2018-12-20,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT03948100
NCT04083183,Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases,Phase 1/Phase 2,Recruiting,Interventional,Non-Malignant Neoplasm,Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10; Fludarabine; Cyclophosphamide; Lapine T-Lymphocyte Immune Globulin; Total-Body Irradiation; Hematopoietic Cell Transplantation; Mycophenolate Mofetil; Sirolimus; Bone Marrow Aspiration; Biospecimen Collection,,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)",40,2020-06-16,2028-01-09,United States,No,https://clinicaltrials.gov/study/NCT04083183
NCT04093167,"A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pembrolizumab,,Canadian Cancer Trials Group,"Cancer Research Institute, New York City; Personal Genome Diagnostics; Mark Foundation for Cancer Research",230,2020-05-26,2027-07-30,Canada; United States,No,https://clinicaltrials.gov/study/NCT04093167
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04155034,MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK),Phase 3,Recruiting,Interventional,Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma,Magnetic Resonance Imaging; Prophylactic Cranial Irradiation,,SWOG Cancer Research Network,National Cancer Institute (NCI),668,2020-05-04,2029-11-15,Canada; Chile; Colombia; Mexico; Saudi Arabia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04155034
NCT04181060,Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 3,Recruiting,Interventional,Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Bevacizumab; Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Osimertinib,,National Cancer Institute (NCI),,300,2020-12-28,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04181060
NCT04253964,Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy,Phase 2,Recruiting,Interventional,Nonsmall Cell Lung Cancer; Performance Status,"Pembrolizumab; Carboplatin; Paclitaxel; Nab paclitaxel; Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13); QLQ-C30 Global Health/Quality of Life Questionnaire; COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes; Pemetrexed",,Wake Forest University Health Sciences,National Cancer Institute (NCI),80,2020-07-01,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT04253964
NCT04300556,"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,Farletuzumab ecteribulin; Prednisone; Prednisolone; Dexamethasone; Lenvatinib,,Eisai Inc.,,182,2020-08-06,2030-08-08,France; Japan; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04300556
NCT04316546,A Multi-Cohort Phase 2 Dose-Escalation Study of MK-7075 (Miransertib) in Proteus Syndrome,Phase 2,Recruiting,Interventional,Proteus Syndrome,MK-7075 (miransertib),,National Human Genome Research Institute (NHGRI),,45,2022-05-20,2028-07-01,United States,No,https://clinicaltrials.gov/study/NCT04316546
NCT04317534,A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153,Phase 2,Recruiting,Interventional,"NSCLC, Stage I",Pembrolizumab,,"Greg Durm, MD",Merck Sharp & Dohme LLC,244,2020-05-05,2029-04-01,United States,No,https://clinicaltrials.gov/study/NCT04317534
NCT04458532,A Randomized Trial to Minimize Non-Response to Aerobic Training in Post-Menopausal Women With Early Stage Breast Cancer,Not Applicable,Recruiting,Interventional,Early Stage Breast Cancer,Aerobic Training; Aerobic Training; Aerobic Training; Aerobic Training,,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),152,2020-10-08,2027-03-31,United States,No,https://clinicaltrials.gov/study/NCT04458532
NCT04486833,"A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung",quaratusugene ozeplasmid; osimertinib; Platinum-Based Chemotherapy,,"Genprex, Inc.",,158,2021-09-03,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT04486833
NCT04551378,Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors,,Recruiting,Observational,COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm,Quality-of-Life Assessment; Survey Administration,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),600,2020-07-13,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT04551378
NCT04577599,Lung B.A.S.E.S 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Assessing Incidence and Stage of Lung Cancer Diagnosis in Subjects Ages 40-54 With a 30 Pack Year History or More Within North and South Carolina,Not Applicable,Recruiting,Interventional,Lung Neoplasms; Lung Cancer,Mobile Low-dose Computed Tomography (LDCT) Screening,,Wake Forest University Health Sciences,Leon Levine Foundation,1160,2021-01-07,2028-10-05,United States,No,https://clinicaltrials.gov/study/NCT04577599
NCT04585477,Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E),Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III,AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy,,Stanford University,AstraZeneca,80,2021-04-08,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT04585477
NCT04762199,"A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Flt3/MerTK Inhibitor MRX-2843; Osimertinib,,Emory University,National Cancer Institute (NCI),69,2021-02-24,2026-12-27,United States,No,https://clinicaltrials.gov/study/NCT04762199
NCT04815356,Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant,Phase 1,Recruiting,Interventional,Hairy Cell Leukemia; Hairy Cell Leukemia Variant,CD22CART cell infusion,,National Cancer Institute (NCI),,27,2022-05-23,2036-12-01,United States,No,https://clinicaltrials.gov/study/NCT04815356
NCT04985032,"Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial",,Recruiting,Observational,Ductal Carcinoma in Situ; Invasive Ductal Carcinoma of Female Breast,stereotactic body radiation therapy,,"RPCR, Inc.",CyberKnife Coalition,200,2022-08-15,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT04985032
NCT04991025,Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers,Phase 2,Recruiting,Interventional,Lung Cancer; Lung Cancer Stage II; Lung Cancer Stage III,Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Certolizumab; Nivolumab,,Memorial Sloan Kettering Cancer Center,,60,2022-10-19,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04991025
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05076760,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Pancreatic Cancer; Triple Negative Breast Cancer; Head and Neck Cancer,MEM-288 Intratumoral Injection; Nivolumab; Docetaxel,,"Memgen, Inc.",H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute,40,2022-04-21,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT05076760
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05168566,"A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Sutetinib Maleate Capsule,,Teligene US,,99,2022-09-01,2026-06-05,China; United States,No,https://clinicaltrials.gov/study/NCT05168566
NCT05261399,"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",Phase 3,Recruiting,Interventional,Carcinoma; Non-Small-Cell Lung,Savolitinib; Osimertinib; Pemetrexed; Cisplatin; Carboplatin,,AstraZeneca,,324,2022-08-03,2026-12-17,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Netherlands; Philippines; Poland; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT05261399
NCT05332925,Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN),,Recruiting,Observational,Lung Cancer; NSCLC; NSCLC Stage IV,Standard of care immune checkpoint inhbitors,,"Jun Zhang, MD, PhD",Nilogen Oncosystems,25,2022-07-21,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05332925
NCT05419375,Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors,Phase 2,Recruiting,Interventional,Solid Tumors,Screening platform,,Hoffmann-La Roche,,15000,2022-07-22,2032-12-22,Australia; Belgium; Brazil; Canada; Chile; Colombia; Costa Rica; France; Germany; Hong Kong; India; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Serbia; Singapore; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05419375
NCT05498428,"A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",Phase 2,Recruiting,Interventional,"Carcinoma, Non-small-Cell Lung",Amivantamab; Lazertinib; Carboplatin; Pemetrexed; Direct Oral Anticoagulant (DOAC); Low Molecular Weight Heparin (LMWH),,"Janssen Research & Development, LLC",,520,2022-11-11,2027-08-17,Brazil; China; France; Germany; Israel; Italy; Japan; Malaysia; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05498428
NCT05500092,"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Resectable Stage IIA to IIIB Non-small Cell Lung Cancer,Nivolumab; (8gy x 3); Platinum Doublet,,Montefiore Medical Center,Bristol-Myers Squibb,52,2023-01-25,2025-07-05,United States,No,https://clinicaltrials.gov/study/NCT05500092
NCT05514717,"A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",Phase 1,Recruiting,Interventional,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Non-Small Cell Lung Cancer; HER2-positive Colorectal Cancer; HER2-positive Tumors; HER2 Low Breast Cancer,XMT-2056,,Mersana Therapeutics,,162,2023-01-24,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT05514717
NCT05578326,Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Lung Cancer; Small-cell Lung Cancer,Trilaciclib; Lurbinectedin,,UNC Lineberger Comprehensive Cancer Center,"G1 Therapeutics, Inc.",30,2022-10-12,2027-12-25,United States,No,https://clinicaltrials.gov/study/NCT05578326
NCT05598879,Global Cardio Oncology Registry,,Recruiting,Observational,Breast Cancer; Hematologic Malignancy; Immune Checkpoint Inhibitor-Related Myocarditis; Cardiotoxicity; Cardiovascular Diseases,anonymized data collection during programmed surveillance clinical follow up,,The Cleveland Clinic,,5000,2022-07-01,2027-07-01,United States,No,https://clinicaltrials.gov/study/NCT05598879
NCT05642572,"A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)",Phase 2,Recruiting,Interventional,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection; Capmatinib; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Ramucirumab,,SWOG Cancer Research Network,National Cancer Institute (NCI),66,2023-05-05,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT05642572
NCT05669846,Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Healthy Donor Fecal Microbiota Transplant (hdFMT); Pembrolizumab,,Diwakar Davar,Gateway for Cancer Research,26,2025-01-08,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT05669846
NCT05702034,"A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack",Phase 3,Recruiting,Interventional,"Ischemic Stroke; Ischemic Attack, Transient",Milvexian; Placebo,,"Janssen Research & Development, LLC",Bristol Myers Squibb Company (BMS),15000,2023-02-15,2026-12-09,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czechia; Denmark; Estonia; Finland; France; Germany; Greece; Hong Kong; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Philippines; Poland; Portugal; Romania; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT05702034
NCT05715229,A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed,,Hackensack Meridian Health,MedSIR,108,2023-09-29,2026-04-28,United States,No,https://clinicaltrials.gov/study/NCT05715229
NCT05720117,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Solid Tumor,PYX-201,,"Pyxis Oncology, Inc",,330,2023-03-14,2027-05-05,Belgium; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05720117
NCT05761782,Engaging Diverse and Underserved Communities in Cancer Awareness Training and Education (EDUCATE),,Recruiting,Observational,Cancer Awareness and Prevention Education,Education,,"University of California, Davis",,1500,2023-03-07,2025-03-07,United States,No,https://clinicaltrials.gov/study/NCT05761782
NCT05785741,"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,DB-1310; Trastuzumab; Osimertinib,,DualityBio Inc.,,1000,2023-04-10,2026-08-31,China; United States,No,https://clinicaltrials.gov/study/NCT05785741
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05845671,"A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors",Phase 1/Phase 2,Recruiting,Interventional,Lung Cancer; Non Small Cell Lung Cancer,Amivantamab 1050mg; Amivantamab 1400mg; Amivantamab (to be determined); Amivantamab (to be determined),,"University of Colorado, Denver","Janssen Research & Development, LLC",12,2023-07-17,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT05845671
NCT05876923,The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients,Not Applicable,Recruiting,Interventional,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Indolent Non-hodgkin Lymphoma,Biospecimen Collection; Cardiopulmonary Exercise Testing; Dual X-ray Absorptiometry; Electronic Health Record Review; Exercise Intervention; Physical Examination; Questionnaire Administration; Spirometry; Physical Performance Testing; Best Practice,,Mayo Clinic,,70,2023-06-12,2028-04-05,United States,No,https://clinicaltrials.gov/study/NCT05876923
NCT05892068,Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Tucatinib,,Memorial Sloan Kettering Cancer Center,Pfizer; Seagen Inc.,28,2023-05-09,2028-05-09,United States,No,https://clinicaltrials.gov/study/NCT05892068
NCT05925803,"A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis",Phase 3,Recruiting,Interventional,Systemic Sclerosis; Scleroderma,"Anifrolumab (blinded); Placebo (blinded); Anifrolumab (unblinded, open label)",,AstraZeneca,,306,2023-11-08,2027-12-31,Austria; Belgium; Canada; China; France; Germany; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Poland; Puerto Rico; Romania; South Africa; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT05925803
NCT06117774,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy",Phase 3,Recruiting,Interventional,Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer,Tarlatamab; Placebo,,Amgen,,400,2024-02-20,2030-05-29,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; China; Colombia; France; Germany; Greece; Hong Kong; Italy; Japan; Mexico; Poland; Portugal; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06117774
NCT06124118,A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC,Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer,carboplatin chemotherapy; NovoTTF-200T (TTFields) System; Durvalumab,,University of Utah,,30,2024-04-04,2026-11-15,United States,No,https://clinicaltrials.gov/study/NCT06124118
NCT06124508,GUIAR: PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors,Not Applicable,Recruiting,Interventional,Head and Neck Cancer,Lung Cancer Screening Education; Semi-Structured Interview; Standard of Care Lung Cancer Screening Program,,University of Miami,LUNGevity Foundation; National Cancer Institute (NCI),44,2024-04-11,2026-04-30,United States,No,https://clinicaltrials.gov/study/NCT06124508
NCT06225804,"A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,ABSK112,,"Abbisko Therapeutics Co, Ltd",,164,2024-02-22,2028-03-05,China; United States,No,https://clinicaltrials.gov/study/NCT06225804
NCT06252129,Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens,Not Applicable,Recruiting,Interventional,Lung Cancer; Lymph Node Metastasis; Pathologic Processes,Subjects undergoing a lung specimen lymph node dissection; Control group,,Brigham and Women's Hospital,,160,2024-07-26,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06252129
NCT06253871,A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations,Phase 1,Recruiting,Interventional,HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer; Brain Metastases From Solid Tumors; Brain Metastases From HER2 and Breast Cancer; CNS Metastases; HER2-Positive Solid Tumors; NSCLC (Non-small Cell Lung Cancer); HER2-positive Bladder Cancer; HER2-positive Colorectal Cancer; HER2 + Gastric Cancer; HER2-positive Gastroesophageal Cancer,IAM1363,,"Iambic Therapeutics, Inc",,243,2024-03-25,2028-03-05,France; Ireland; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253871
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06312137,A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery,Phase 3,Recruiting,Interventional,Non Small Cell Lung Cancer,Sacituzumab tirumotecan; Pembrolizumab; Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Paclitaxel; Rescue medication,,Merck Sharp & Dohme LLC,,780,2024-04-03,2034-10-23,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Peru; Poland; Portugal; Romania; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06312137
NCT06385262,"Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301",Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Alirocumab; Cemiplimab; Chemotherapy,,Duke University,Regeneron Pharmaceuticals,126,2025-03-17,2029-10-30,United States,No,https://clinicaltrials.gov/study/NCT06385262
NCT06400472,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms",LY4170156; bevacizumab; carboplatin; Itraconazole; pembrolizumab,,Eli Lilly and Company,,495,2024-05-20,2027-04-05,Australia; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06400472
NCT06401330,Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT),Phase 3,Recruiting,Interventional,Stage I Mixed Cell Type Kidney Wilms Tumor; Stage II Mixed Cell Type Kidney Wilms Tumor; Stage III Mixed Cell Type Kidney Wilms Tumor; Stage IV Mixed Cell Type Kidney Wilms Tumor,Bone Scan; Carboplatin; Computed Tomography; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Irinotecan; Magnetic Resonance Imaging; Nephrectomy; Patient Observation; Positron Emission Tomography; Ultrasound Imaging; Vincristine; X-Ray Imaging,,Children's Oncology Group,,1656,2025-04-15,2031-02-13,Canada; United States,No,https://clinicaltrials.gov/study/NCT06401330
NCT06422143,Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer,Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer; NSCLC,Pembrolizumab; sac-TMT; Carboplatin; Paclitaxel; Nab-paclitaxel,,Merck Sharp & Dohme LLC,,851,2024-06-10,2031-02-12,Argentina; Austria; Brazil; Canada; Chile; China; Colombia; Czechia; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Peru; Poland; Romania; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06422143
NCT06426628,Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier,,Recruiting,Observational,"Pulmonary Nodule, Solitary; Lung Cancer",,,"Veracyte, Inc.",,2400,2022-07-18,2027-03-31,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06426628
NCT06462365,"Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)",Phase 1,Recruiting,Interventional,"Hematologic Malignancy; GvHD; GVHD,Acute; GVHD, Chronic; Hematopoietic Stem Cell Transplant; Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, Adult T-Cell; Acute Myeloid Leukemia in Remission; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia, in Remission; Cancer Remission",TRX103,,"Tr1X, Inc.",,36,2024-04-08,2027-04-15,United States,No,https://clinicaltrials.gov/study/NCT06462365
NCT06494488,Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL),Early Phase 1,Recruiting,Interventional,Lipid Metabolism Disorders; Hypertriglyceridemia,EPA; DHA,,The Miriam Hospital,"National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)",80,2025-07-10,2028-03-31,United States,No,https://clinicaltrials.gov/study/NCT06494488
NCT06545331,A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors,Phase 1,Recruiting,Interventional,Locally Advanced or Metastatic Solid Tumors; Esophageal Squamous Cell Cancer; Head and Neck Squamous Cell Cancer; NSCLC (Non-small Cell Lung Cancer); Hormone-receptor-positive Breast Cancer; Triple Negative Breast Cancer (TNBC),XB010; Pembrolizumab,,Exelixis,,396,2024-08-06,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT06545331
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06561386,"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Nivolumab; Relatlimab; Pembrolizumab; Carboplatin; Pemetrexed; Cisplatin,,Bristol-Myers Squibb,,1000,2024-10-07,2032-08-04,Argentina; Australia; Austria; Belgium; Brazil; Chile; China; Colombia; Denmark; France; Germany; India; Ireland; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; Romania; Saudi Arabia; South Africa; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06561386
NCT06566443,Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Honokiol,,The Methodist Hospital Research Institute,,15,2024-11-08,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT06566443
NCT06593522,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,MTAP-deleted NSCLC,AMG 193,,Amgen,,200,2024-12-26,2030-11-29,Australia; Brazil; Canada; China; Czechia; Hong Kong; Japan; Latvia; Netherlands; Portugal; Singapore; South Korea; Switzerland; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06593522
NCT06659458,Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients,,Recruiting,Observational,Lung Cancer - Non Small Cell; EGFR Exon 19 Deletion Mutation,blood draw; Gene sequencing,,Our Lady of the Lake Hospital,,20,2025-01-01,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT06659458
NCT06671613,Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer,Not Applicable,Recruiting,Interventional,Stage IV NSCLC; NSCLC; Immunotherapy; Fasting Mimicking Diet,FMD; Regular Diet Plus FMD,,VA Office of Research and Development,Indiana University; US Department of Veterans Affairs Cooperative Studies Program; L-Nutra Inc,66,2025-10-27,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT06671613
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06706076,"A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)",Phase 1/Phase 2,Recruiting,Interventional,NSCLC (Advanced Non-small Cell Lung Cancer),BH-30643; BH-30643,,BlossomHill Therapeutics,,266,2025-01-09,2029-07-31,Australia; Canada; Hong Kong; Japan; Malaysia; Singapore; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06706076
NCT06712745,Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung,Early Phase 1,Recruiting,Interventional,"Cancer, Lung; Metastasis",Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR),,University of Texas Southwestern Medical Center,Elekta Limited,30,2025-09-19,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06712745
NCT06716580,EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations,Not Applicable,Recruiting,Interventional,Lung Cancer; EGFR Gene Mutation,Circulating Tumor DNA (ctDNA) Assay,,Dana-Farber Cancer Institute,Beth Israel Deaconess Medical Center; Boston Medical Center; Massachusetts General Hospital,1000,2025-04-01,2030-09-01,United States,No,https://clinicaltrials.gov/study/NCT06716580
NCT06814496,RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3,Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer; Merkel Cell Carcinoma,Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy,,University of Arizona,Amgen,30,2025-09-08,2030-05-05,United States,No,https://clinicaltrials.gov/study/NCT06814496
NCT06896162,PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival,Not Applicable,Recruiting,Interventional,Solid Tumor Malignancies; Metastatic Cancer; Breast Cancer; Colorectal Cancer; Lung Cancer; Bladder Cancer,Expert Review; Blood or tissue samples collection.; The Precision Oncology Navigation,,UNC Lineberger Comprehensive Cancer Center,Eli Lilly and Company,500,2025-06-27,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT06896162
NCT06973564,"A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,JAB-23E73; JAB-23E73; JAB-23E73,,"Jacobio Pharmaceuticals Co., Ltd.",,294,2025-05-29,2028-02-05,United States,No,https://clinicaltrials.gov/study/NCT06973564
NCT07064395,Bright Light Therapy to Reduce Sleep Disturbance and Biological Aging in Lung Cancer Patients,Not Applicable,Recruiting,Interventional,Lung Cancers,bright light,,Henry Ford Health System,Michigan State University,20,2025-06-09,2026-02-28,United States,No,https://clinicaltrials.gov/study/NCT07064395
NCT07125183,A Phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma of Soft Tissue,Phase 2,Recruiting,Interventional,Sarcoma,Doxorubicin,,"University of Colorado, Denver",Cancer League of Colorado,20,2025-12-05,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT07125183
NCT07132918,The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers,Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer (Stage III); Esophageal Cancer Stage I-III; Esophagogastric Cancer Stage I-III; Thymoma and Thymic Carcinoma Stage II-III; Other Cancers in the Thoracic Region,MRgART; LINAC,,"University of Wisconsin, Madison","National Heart, Lung, and Blood Institute (NHLBI)",60,2025-10-08,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT07132918
NCT07155187,Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI,Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Telisotuzumab Adizutecan; Standard of Care,,AbbVie,,430,2025-12-10,2030-09-05,Australia; Israel; Japan; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT07155187
NCT07158749,Generalized and Domain-Specific Episodic Thinking for Smoking Cessation: An 8-Week Pilot and Feasibility Trial,Not Applicable,Not yet recruiting,Interventional,Cigarette Smoking Behavior,Episodic Future Thinking (EFT); Episodic Recent Thinking (ERT); Domain-specific episodic thinking; Generalized episodic thinking,,Virginia Polytechnic Institute and State University,National Cancer Institute (NCI); Roswell Park Comprehensive Cancer Center,134,2026-01-01,2027-05-01,United States,No,https://clinicaltrials.gov/study/NCT07158749
NCT07192900,Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease: A Phase I Trial,Phase 1,Not yet recruiting,Interventional,"Malignant Pleural Effusion; Malignant Mesothelioma; Pleural Effusion, Malignant; Metastasis to Pleura",locally manufactured adoptive cellular therapy (ACT) product; Interleukin-2,,"David Bartlett, MD","Miltenyi Biotec, Inc.; Iovance Biotherapeutics, Inc.; UPMC Hillman Cancer Center",10,2025-10-05,2037-10-05,United States,No,https://clinicaltrials.gov/study/NCT07192900
NCT07231159,"Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots",,Recruiting,Observational,Breast Cancer; Lung Cancer (Diagnosis); Prostate Cancer,referral for definitive diagnosis based on their cancer screening results; Engagement,,AdventHealth,Florida Department of Health,200,2025-11-17,2026-08-31,United States,No,https://clinicaltrials.gov/study/NCT07231159
